All major drug classes covered
Risk levels for each
Serotonin syndrome explained
Microdosing Psilocybin Drug Interactions: Complete Guide
Every documented and theorised interaction between psilocybin and prescription medications, psychiatric drugs, recreational substances, and common supplements — with risk levels, mechanisms, and clear guidance for each.
This page is for educational and harm reduction purposes only — not medical advice. Do not stop, adjust, or combine medications without consulting a qualified healthcare provider. Psilocybin is a controlled substance in most jurisdictions. If you take any prescription medication, review this guide with a psychedelic-informed physician before proceeding.
Medication interactions are the single most practically important safety consideration for the majority of people who microdose. Most serious adverse events in self-administered psychedelic use involve combinations with other substances — often substances the person did not think to check. This guide is the most comprehensive reference we have compiled. Read it fully, not just the sections you think are relevant.
How Psilocybin Drug Interactions Work
Psilocybin's interactions with other substances occur through several distinct mechanisms. Understanding which mechanism is driving an interaction helps you assess its severity and why the guidance exists.
Serotonergic mechanisms
Psilocybin converts to psilocin, which is a potent serotonin 2A (5-HT2A) receptor agonist. It also has activity at multiple other serotonin receptor subtypes. Any other substance that increases serotonin levels, activates serotonin receptors, or inhibits serotonin breakdown can produce additive or synergistic serotonergic effects — ranging from blunted psilocybin effect (SSRIs, due to receptor downregulation) to potentially dangerous serotonin excess (MAOIs, due to prevented serotonin breakdown).
Pharmacokinetic mechanisms
Psilocybin is metabolised by alkaline phosphatases in the gut and blood, and psilocin is further metabolised by MAO enzymes and other hepatic pathways. Substances that inhibit or induce these enzymes can increase or decrease psilocin availability — changing the effective dose even if the weighed amount is unchanged. This is a less-studied interaction class for psilocybin specifically but is relevant for several commonly used medications.
Cardiovascular mechanisms
Psilocybin produces mild, transient increases in heart rate and blood pressure through its serotonergic and sympathomimetic properties. Combined with other substances affecting cardiovascular parameters — stimulants, certain antihypertensives, cardiac medications — these effects can be additive or, in some cases, interact in less predictable ways.
CNS depression and stimulation
Psilocybin has a mild stimulant quality in the acute window. Combining with strong CNS depressants (alcohol, benzodiazepines) tends to blunt its effects. Combining with stimulants (amphetamines, cocaine) may produce unpredictable cardiovascular and psychological effects through additive sympathomimetic mechanisms.
THE DATA GAP |
Most interaction data for psilocybin comes from case reports, pharmacological inference from related compounds, and clinical trial exclusion criteria — not from controlled human interaction studies. This means "unknown" is a genuinely important category on this page, not a placeholder. Unknown does not mean safe. It means the data to make a confident safety assessment does not exist, and caution is appropriate.
Risk Level Reference
Every interaction on this page is assigned one of four risk levels. These are applied consistently throughout the guide.
🚫 Avoid
Hard contraindication. Documented serious risk. Do not combine under any circumstances without direct medical supervision.
⚠ Caution
Significant interaction risk or meaningful effect on psilocybin activity. Professional guidance required before proceeding.
👁 Monitor
Possible interaction with lower severity. Proceed with awareness, track carefully, and be prepared to stop.
✓ Low concern
No significant interaction expected at therapeutic doses. Inform your prescriber; standard microdosing precautions apply.
Master Interaction Table
A complete reference covering all major substance classes. For detailed guidance on any category, see the dedicated sections below.
SUBSTANCE/ CLASS | EXAMPLES | RISK LEVEL | PRIMARY CONCERN | KEY GUIDANCE |
|---|---|---|---|---|
MAOIs | Phenelzine, tranylcypromine, selegiline, isocarboxazid | Avoid | Serotonin syndrome; dramatically potentiates psilocybin | Hard stop. Never combine. |
Lithium | Lithobid, Eskalith, lithium citrate | Avoid | Seizure risk documented in multiple case reports | Hard stop. Never combine. |
Tramadol | Ultram, Conzip | Avoid | Serotonin syndrome risk; opioid-serotonergic dual mechanism | Do not combine. Discuss with prescriber. |
SSRIs | Lexapro, Zoloft, Prozac, Paxil, Celexa | Caution | 5-HT2A downregulation significantly blunts psilocybin effect | Do not stop without medical supervision. Discuss with prescriber. |
SNRIs | Effexor, Cymbalta, Pristiq, Fetzima | Caution | Similar to SSRIs; dual mechanism adds complexity; serotonin syndrome risk at high doses | Medical guidance required. |
Tricyclic antidepressants | Amitriptyline, nortriptyline, clomipramine, imipramine | Caution | Serotonergic and anticholinergic overlap; unpredictable interaction | Medical guidance required. |
Antipsychotics | Quetiapine, risperidone, aripiprazole, olanzapine, haloperidol | Caution | 5-HT2A antagonism may blunt or unpredictably alter effects; underlying diagnosis often also contraindicated | Medical guidance essential; underlying condition review required. |
Mood stabilisers (non-lithium) | Lamotrigine, valproate, carbamazepine | Caution | Variable interaction profiles; lamotrigine may reduce effects; carbamazepine enzyme induction | Do not adjust without prescriber. Discuss explicitly. |
Cannabis / THC | All THC-containing products | Caution | Synergistic psychoactive effects; unpredictable anxiety amplification | Avoid on dose days. Do not combine in first cycles. |
St. John's Wort | Hypericum perforatum supplements | Caution | Serotonergic activity; MAO inhibition; serotonin syndrome risk | Treat as equivalent to mild SSRI. Discuss with provider. |
MDMA / ecstasy | All MDMA-containing products | Caution | Strong serotonin releasing agent; serotonin syndrome risk; cardiovascular strain | Do not combine. High serotonin syndrome risk when combined. |
ADHD stimulants | Adderall, Vyvanse, Ritalin, Concerta, Strattera | Monitor | Different neurotransmitter systems; community reports mixed; possible anxiety amplification | No hard contraindication; proceed with awareness and medical input. |
Alcohol | All alcoholic beverages | Monitor | CNS depressant; disrupts serotonin signalling; counteracts microdosing intent; dehydration | Avoid on dose days and the day before. Counterproduct |
Beta blockers | Propranolol, metoprolol, atenolol | Monitor | Propranolol may modestly reduce some psilocybin effects; cardiovascular parameter interaction | Likely benign at therapeutic doses. Inform prescriber. |
Triptans (migraine) | Sumatriptan, rizatriptan, eletriptan | Monitor | Serotonin receptor activity overlap; theoretical serotonin syndrome risk at high doses | Do not combine on same day. Separate by at least 24 hours. |
Benzodiazepines | Xanax, Valium, Klonopin, Ativan | Low concern | GABAergic; will blunt and potentially terminate psilocybin effects (used therapeutically for this) | Not a safety risk; will reduce effects. Watch for benzo dependency. |
Common analgesics | Ibuprofen, paracetamol/acetaminophen, aspirin | Low concern | No significant psilocybin interaction expected at standard doses | Generally safe. High-dose NSAIDs: inform prescriber. |
Antihistamines | Diphenhydramine, cetirizine, loratadine | Low concern | Diphenhydramine has mild serotonin activity; others low concern | Generally safe. Diphenhydramine may slightly blunt effects. |
Hormonal contraceptives | Combined pill, mini-pill, IUD, implant | Low concern | No significant psilocybin interaction documented | No specific guidance needed. Inform prescriber generally. |
Statins | Atorvastatin, simvastatin, rosuvastatin | Low concern | No significant psilocybin interaction expected | Generally safe. Inform prescrib |
Proton pump inhibitors | Omeprazole, lansoprazole, pantoprazole | Low concern | Possible minor reduction in psilocybin absorption via pH change — theoretical | Generally safe. Minor effect if any.
|
DON'T STOP TAKING YOUR MEDICATION TO MICRODOSE WITHOUT PSYCHEDELIC-INFORMED MEDICAL SUPERVISION |
Never discontinue, reduce, or taper a prescription medication in order to microdose psilocybin without medical supervision. Withdrawal from SSRIs, antipsychotics, mood stabilisers, and many other psychiatric medications can cause serious and sometimes dangerous effects. If you want to explore microdosing while on medication, the correct path is a conversation with a psychedelic-informed prescriber — not unilateral medication cessation.
Serotonin syndrome is the interaction risk most associated with psilocybin, and the most serious one outside of lithium-associated seizures. It occurs when excess serotonergic activity in the nervous system causes a characteristic and potentially dangerous cluster of symptoms. Understanding it is essential for anyone combining psilocybin with any serotonergic substance.
How it develops
Serotonin syndrome most commonly results from combinations of two or more serotonergic agents — for example, a serotonin reuptake inhibitor combined with a serotonin-releasing agent, or either combined with a substance that prevents serotonin breakdown (MAOIs). With psilocybin, the primary risk categories are combining with MAOIs (highest risk), SNRIs at higher doses, or MDMA. The syndrome can develop within minutes to hours of the problematic combination.
Mild symptoms
-
Rapid heart rate
-
Shivering or goosebumps
-
Sweating
-
Dilated pupils
-
Intermittent tremor
-
Myoclonus (muscle twitching)
Moderate symptoms
-
Hyperthermia (elevated temperature)
-
Hyperreflexia
-
Clonus (rhythmic muscle contractions)
-
Agitation or restlessness
-
Confusion or disorientation
-
Pronounced blood pressure changes
SEVERE SYMPTOMS
-
High fever (above 41°C / 106°F)
-
Seizures
-
Irregular heartbeat
-
Loss of consciousness
-
Rhabdomyolysis
-
Metabolic acidosis
IF YOU SUSPECT SEROTONIN SYNDROME |
Call emergency services immediately (911 / 999 / 000 / 112). Tell them what substances have been taken and when. Do not wait to see if symptoms resolve — serotonin syndrome can escalate rapidly. In hospital, benzodiazepines are used for agitation; cyproheptadine (a serotonin antagonist) may be administered. The syndrome is treatable when caught early.
Psychiatric Medications: Detailed Guidance
MAOIs — Monoamine Oxidase Inhibitors
Phenelzine · Tranylcypromine · Selegiline · Isocarboxazid · Moclobemide
MAOIs prevent the breakdown of monoamine neurotransmitters including serotonin, by inhibiting the MAO enzymes responsible for their metabolism. Combined with psilocybin — which directly activates serotonin receptors — this creates a dangerous excess of serotonergic activity with significant serotonin syndrome risk. This is a hard contraindication with no safe threshold.
Note that selegiline at low doses (used for Parkinson's disease or depression) is a selective MAO-B inhibitor and carries somewhat lower but still significant risk. Moclobemide (a reversible MAOI used in some countries) requires a minimum 24-hour washout period before any serotonergic substance — and given the stakes, treating it the same as irreversible MAOIs is the safest approach.
Also note: some dietary supplements — high-dose Syrian rue (Peganum harmala), passionflower in large amounts, and certain ayahuasca preparations — have MAOI activity. These carry the same interaction risk.
LITHIUM
Lithobid · Eskalith · Lithium citrate
Multiple case reports document seizures in people combining psychedelics including psilocybin with lithium. The mechanism is not fully characterised — lithium may lower the seizure threshold, interact with psychedelic-induced physiological changes, or produce effects via altered second-messenger systems. The pattern across case reports is consistent enough to constitute a hard contraindication.
Lithium has a narrow therapeutic window, meaning small changes in lithium levels can have significant effects. Anything affecting hydration, sodium intake, or kidney function — which psilocybin's physiological effects may do to a minor degree — can shift lithium into toxic or sub-therapeutic ranges. This adds a second mechanism of concern beyond the seizure risk.
SSRIs — Selective Serotonin Reuptake Inhibitors
Lexapro · Zoloft · Prozac · Paxil · Celexa · Luvox
SSRIs are not a hard contraindication in the way MAOIs and lithium are, but they represent the most practically important interaction for microdosing because of how many people take them. The interaction mechanism is 5-HT2A receptor downregulation: chronic SSRI use causes the brain to reduce 5-HT2A receptor density and sensitivity — the very receptor through which psilocybin produces its effects. The result is that microdosing while on SSRIs frequently produces little or no detectable effect, leading people to escalate dose to compensate.
The degree of blunting varies between individuals and between specific SSRIs. Fluoxetine (Prozac) — with its longest half-life — tends to produce the most pronounced blunting. Escitalopram (Lexapro) and sertraline (Zoloft) are somewhat less predictable. Fluvoxamine (Luvox) additionally inhibits CYP enzymes involved in psilocin metabolism, which could theoretically increase psilocin exposure.
There is a low theoretical serotonin syndrome risk at standard doses given SSRIs' reuptake mechanism rather than direct receptor activation — but this risk increases at higher psilocybin doses or with concurrent use of other serotonergic substances. The primary practical concern remains blunting and dose escalation rather than serotonin toxicity at true microdose levels.
Antipsychotics
Quetiapine · Risperidone · Aripiprazole · Olanzapine · Haloperidol · Clozapine
Most antipsychotics act as 5-HT2A antagonists — they block the same receptor that psilocybin activates. This means antipsychotics can significantly blunt or completely block psilocybin's effects. The interaction may appear "safe" in the sense of preventing psychedelic effects, but it reflects a pharmacological opposition rather than a neutral combination. Unpredictable interactions with dopaminergic effects are an additional concern.
Crucially, the underlying diagnoses for which antipsychotics are prescribed — schizophrenia, schizoaffective disorder, bipolar I, severe psychosis — are themselves hard contraindications for psilocybin use. The medication interaction question is therefore secondary to the underlying condition contraindication for most people in this category.
Aripiprazole (Abilify) is a partial agonist at 5-HT2A and has a more complex interaction profile than pure antagonists — its partial agonism may produce less blunting but creates less predictable pharmacology in combination.
Mood Stabilisers (Non-Lithium)
Lamotrigine · Valproate / Valproic acid · Carbamazepine · Oxcarbazepine
Lamotrigine (Lamictal) has been studied in the context of psychedelic interactions more than most mood stabilisers. It is a glutamate antagonist and sodium channel blocker — its interaction with psilocybin is not strongly serotonergic. Some research suggests lamotrigine may reduce the intensity of psychedelic effects, potentially by stabilising the neural excitability that psilocybin increases. At microdose levels, the interaction is unlikely to produce a serious adverse effect, but the underlying condition (bipolar II, epilepsy) may itself represent a caution.
Carbamazepine and oxcarbazepine are potent inducers of CYP enzymes (particularly CYP3A4). While psilocybin's metabolism is not primarily CYP-dependent, these inducers may affect downstream psilocin clearance in ways that are not fully characterised. They also significantly lower seizure threshold when suddenly withdrawn — adding complexity to any decision about changing this medication in relation to microdosing.
Valproate has mild serotonergic properties in addition to its mood-stabilising mechanisms. The combination with psilocybin is not well-characterised but is generally considered lower risk than lithium or carbamazepine combinations.
ADHD Medications: Monitor Category
Stimulant Medications
Adderall · Vyvanse · Ritalin · Concerta · Focalin · Dexedrine
Amphetamine-based stimulants (Adderall, Vyvanse) and methylphenidate-based stimulants (Ritalin, Concerta) primarily increase dopamine and norepinephrine availability — different neurotransmitter systems from psilocybin's primary serotonergic action. This is why the interaction profile is more uncertain than with serotonergic drugs rather than clearly dangerous.
Community reports are genuinely mixed: some people report no interaction; others report that stimulants on dose days produce heightened anxiety, overstimulation, or an uncomfortable "too much" feeling. The proposed mechanism is additive sympathomimetic effects — both psilocybin and stimulants have mild to moderate cardiovascular activating properties that may compound.
A common harm reduction practice is to avoid taking both on the same day — either microdosing on days not taking stimulants, or not taking the stimulant medication on dose days. This is a personal harm reduction choice, not an evidence-based recommendation. Any decision to skip or delay prescribed ADHD medication should be discussed with the prescribing physician.
Non-Stimulant ADHD Medications
Strattera (atomoxetine) · Intuniv / Kapvay (guanfacine / clonidine) · Wellbutrin (bupropion)
Atomoxetine (Strattera) is a selective norepinephrine reuptake inhibitor. Its interaction with psilocybin is poorly characterised — insufficient data for confident guidance beyond general caution and prescriber awareness.
Guanfacine and clonidine are alpha-2 adrenergic agonists. Their cardiovascular effects (blood pressure lowering) theoretically interact with psilocybin's mild blood pressure-raising effects, potentially in a partially offsetting manner. No significant adverse interactions are documented, but the combination warrants monitoring.
Bupropion (Wellbutrin) is used for both ADHD and depression. It inhibits dopamine and norepinephrine reuptake and has mild serotonergic activity. It also lowers the seizure threshold — an important consideration given the lithium-associated seizure risk and the broader caution about seizure threshold in any psilocybin combination.
Cardiovascular Medications
beta blockers
Monitor
Propranolol has been used in psychedelic research as a pre-treatment that partially modulates effects via beta-adrenergic blockade. At therapeutic doses for hypertension or anxiety, likely to mildly modulate but not dangerously interact. Inform your prescriber.
ACE inhibitors / ARBs
Low concern
Blood pressure medications of this class do not have significant pharmacological overlap with psilocybin's mechanisms. The mild BP-raising effect of psilocybin is unlikely to produce clinically significant changes in people well-controlled on these medications.
Calcium channel blockers
Low concern
No significant psilocybin interaction documented or mechanistically predicted. Standard precautions apply. Inform your prescriber.
Digoxin / cardiac glycosides
Monitor
Narrow therapeutic window medication. Psilocybin's cardiovascular effects — even mild — warrant caution when combined with a medication requiring precise cardiac monitoring. Discuss with prescriber and cardiologist before proceeding.
Anticoagulants (warfarin, apixaban)
Low concern
No significant pharmacological interaction expected. However, any use of substances while on anticoagulation therapy warrants physician awareness given the consequences of interactions in this context.
QT-prolonging medications
Monitor
Some antiarrhythmics, antipsychotics, and antibiotics prolong the QT interval. Psilocybin has mild cardiovascular effects that, combined with a QT-prolonging drug, could theoretically increase arrhythmia risk. Discuss with your cardiologist or prescriber.
recreational substances
cannabis (thc)
All THC-containing products — flower, edibles, concentrates, vapes
Cannabis is the most commonly combined substance in the microdosing community, and the interaction is more significant than most people expect. THC and psilocybin interact synergistically in the psychoactive domain — THC dramatically amplifies psychedelic effects at doses that would otherwise be sub-perceptual. This has been documented repeatedly in community reports: people who combine a genuine microdose with cannabis often find the combination produces a noticeable psychedelic-adjacent experience.
The practical implication is unambiguous: do not combine cannabis with psilocybin on dose days, particularly in your first cycles before you know your individual response. This includes CBD products with any THC content. Pure CBD without THC has a different pharmacological profile and lower interaction concern, though research is limited.
For people who use cannabis daily for pain, anxiety, or sleep, this requires planning dose days accordingly. It does not mean you must stop using cannabis entirely — it means the combination on dose days is not safe for calibration or predictable microdosing practice.
Alcohol
Beer, wine, spirits — any alcoholic product
Alcohol is a CNS depressant that disrupts serotonin signalling and significantly impairs the subtle, reflective quality that makes microdosing useful. Combining alcohol on dose days tends to counteract the intended effects, muddy your tracking data, and — at higher doses — interact with psilocybin's cardiovascular effects. Heavy drinking the day before a dose day can also affect baseline state in ways that distort your observations.
This is less a safety concern and more a harm reduction and efficacy concern: alcohol on dose days is counterproductive to the practice's goals and makes honest self-assessment nearly impossible.
MDMA / Ecstasy
3,4-methylenedioxymethamphetamine and its variants
MDMA causes massive serotonin release — a fundamentally different mechanism from psilocybin's receptor agonism, but one that creates strong serotonin syndrome risk when combined. The combination is sometimes called "candy flipping" in recreational contexts and is documented as producing significantly more intense and unpredictable effects than either substance alone. At the doses and combinations involved in recreational use, this is a high-risk combination. Even at microdose psilocybin levels combined with recreational MDMA doses, the serotonin syndrome risk is not trivial.
Do not combine. The interaction risk is high regardless of which dose is "small."
Cocaine
Caution
Strong CNS stimulant and cardiovascular activator. Combined with psilocybin's mild sympathomimetic effects: additive cardiovascular strain, unpredictable psychological effects, anxiety amplification. Avoid on dose days.
opiates (illicit)
Monitor
Standard opioids (heroin, oxycodone) have low direct serotonergic activity. Primary concern is CNS depressant interaction and general impairment on dose days. Tramadol (an opioid with significant serotonergic activity) is a separate, harder contraindication — see main table.
ketamine
Monitor
NMDA antagonist with dissociative and antidepressant properties. Limited interaction data with psilocybin. Additive dissociative effects possible. Not recommended to combine without medical oversight, particularly given the polypharmacy complexity.
caffeine
Low concern
No significant psilocybin interaction. High caffeine consumption on dose days may amplify anxiety — this is not a pharmacological interaction but a lifestyle one. Moderate caffeine is generally fine.
supplements and herbal products
Many people do not think of supplements as substances requiring interaction checks. Several commonly used supplements have meaningful serotonergic activity or enzyme-inhibiting properties that are relevant to psilocybin.
St. John's Wort
Caution
Has serotonergic activity via serotonin reuptake inhibition and mild MAO inhibition. Treat as equivalent to a mild SSRI for interaction purposes. Serotonin syndrome risk when combined with psilocybin — particularly at higher doses of either. Also a potent CYP3A4 inducer affecting many drug metabolisms.
5-HTP (5-hydroxytryptophan)
Caution
Direct serotonin precursor — increases serotonin synthesis. Combined with psilocybin's receptor activation, there is a theoretical serotonin syndrome risk, particularly at higher 5-HTP doses. Do not take 5-HTP on dose days or the day before.
SAMe (S-adenosyl methionine)
Caution
SAMe has antidepressant properties via serotonergic and other monoaminergic effects. Serotonin syndrome risk when combined with other serotonergic agents. Avoid combining with psilocybin on dose days.
Lion's Mane mushroom
Low concern
The primary component of the Stamets Stack. No significant serotonergic interaction. NGF-promoting activity is mechanistically distinct from serotonin pathways. Generally considered safe to combine — this combination is the basis of the Stamets Protocol.
Niacin (vitamin B3)
Low concern
Used in the Stamets Stack. No significant interaction with psilocybin's pharmacological mechanisms. The "flush" reaction (warmth, redness) at 50–100mg doses is a prostaglandin effect — uncomfortable but not dangerous. Separate concern: high-dose niacin can affect liver enzymes with long-term use.
Valerian / Passionflower
Monitor
These herbs have mild GABAergic and potentially mild serotonergic activity. Will likely blunt rather than amplify psilocybin effects. Large doses of passionflower have documented MAOI activity — treat high doses with the same caution as mild MAOIs.
Melatonin
Low concern
No significant psilocybin interaction. Melatonin is structurally related to serotonin but acts at its own receptors. Standard doses are generally considered safe to use for sleep on off days.
Magnesium
Low concern
No significant interaction with psilocybin's pharmacological mechanism. Some microdosers report taking magnesium glycinate to reduce headaches — no evidence against this practice.
general and common medicines
antibiotics
Low concern
Most antibiotics have no significant psilocybin interaction. Exception: fluoroquinolones (ciprofloxacin, levofloxacin) are mild QT prolongers — see cardiovascular section. Gut-altering antibiotics may affect psilocybin absorption via microbiome effects, though this is theoretical.
Corticosteroids
Monitor
Systemic corticosteroids can affect mood and cognition independently. Combined with psilocybin's mood-amplifying properties on dose days, monitoring for amplified mood effects is warranted. No direct pharmacological interaction documented.
thyroid medication
Low concern
Levothyroxine and other thyroid medications have no significant psilocybin interaction. Untreated hypothyroidism or hyperthyroidism can affect mood and cognitive state — relevance to dose-day experience is via underlying condition, not direct drug interaction.
diabetes
Low concern
No significant psilocybin interaction documented. Appetite changes on dose days are relevant to blood glucose management in diabetes — monitor accordingly and ensure eating schedule is not significantly disrupted by dose-day appetite suppression.
IF YOUR MEDICATION IS NOT LISTED |
The absence of a medication from this guide does not mean it is safe to combine with psilocybin. It means we do not have sufficient data to characterise the interaction, or the interaction risk is very low based on mechanism. If you take any medication not covered here, the appropriate response is to discuss it with a psychedelic-informed physician who can evaluate your specific combination against current pharmacological knowledge.
If You Experience a Reaction: What to Do
Signs of a potentially serious interaction
The following symptoms occurring after taking psilocybin — particularly if combined with any medication — warrant immediate medical attention: rapid heartbeat with agitation and muscle rigidity (possible serotonin syndrome); seizure activity of any kind; severe confusion or loss of consciousness; extreme hyperthermia (very high body temperature); or any symptom that feels physically dangerous rather than psychologically uncomfortable.
CALL EMERGENCY SERVICES FOR ANY OF THE ABOVE |
Tell the responders what substances have been taken and when. If you cannot speak, have someone with you who knows what you have taken. Medical personnel are bound by confidentiality and their priority is your safety, not prosecution. The information you provide helps them treat you correctly.
Signs of a non-emergency difficult experience
If you feel anxious, emotionally overwhelmed, or that the dose was stronger than expected, but do not have physical symptoms suggesting a medical emergency: move to a safe, quiet space; slow your breathing; contact a trusted support person; and do not drive or operate machinery. Most non-emergency difficult experiences resolve within a few hours. Taking a benzodiazepine (if you have a prescription) can terminate a psilocybin experience if needed.
FAQ — Psilocybin Drug Interactions
Is it safe to microdose on antidepressants?
It depends on the antidepressant. SSRIs and SNRIs are not hard contraindications but significantly blunt psilocybin's effects through 5-HT2A receptor downregulation, meaning microdosing while on them often produces little or no benefit. MAOIs are a hard contraindication — do not combine under any circumstances due to serotonin syndrome risk. Tricyclics and other antidepressants require individual assessment. Do not stop any antidepressant without medical supervision to microdose — antidepressant discontinuation carries serious risks.
Can I take ibuprofen or paracetamol on a dose day?
Yes — standard doses of ibuprofen, paracetamol (acetaminophen), and aspirin have no significant pharmacological interaction with psilocybin. These are among the safest common medications to use on dose days. The primary caveat is that high-dose or regular NSAID use should be disclosed to a prescriber for general health reasons independent of microdosing.
What medications are the most dangerous to combine with psilocybin?
The two hardest contraindications with the most serious documented risks are MAOIs (serotonin syndrome risk — potentially life-threatening) and lithium (seizure risk documented in multiple case reports). Tramadol, which has both opioid and serotonergic mechanisms, also carries significant serotonin syndrome risk. MDMA combined with psilocybin is dangerous due to additive serotonergic effects regardless of which is at a "small" dose. After these, SSRIs and antipsychotics represent significant but less acutely dangerous interactions.
Can I microdose if I take St. John's Wort?
St. John's Wort has serotonergic activity through serotonin reuptake inhibition and mild MAO inhibition — treat it as pharmacologically equivalent to a mild SSRI combined with a very weak MAOI. This creates a meaningful serotonin syndrome risk when combined with psilocybin, particularly at higher doses of either. Stop St. John's Wort for at least two weeks before microdosing, and discuss with a healthcare provider. Do not stop any prescribed medication to take St. John's Wort without medical guidance.
Why does cannabis amplify microdosing so much?
THC and psilocybin have synergistic psychoactive effects through different but complementary mechanisms — THC acts primarily on endocannabinoid receptors (CB1), while psilocybin acts on serotonin receptors. These systems interact in ways that amplify altered states significantly beyond what either produces alone. A true microdose combined with cannabis can produce an experience closer to a threshold psychedelic dose than a sub-perceptual one. This is consistently reported in community data and reflects a genuine pharmacological interaction, not simply a psychological one.
How long should I wait after stopping an SSRI before microdosing?
This question contains a critical premise worth addressing first: do not stop an SSRI in order to microdose without medical supervision. SSRI discontinuation syndrome can be serious, and the decision to taper off an antidepressant should be made for therapeutic reasons, with physician guidance, using a gradual taper schedule. If you have already stopped an SSRI under medical supervision, receptor density typically begins restoring within 2–4 weeks, though full restoration can take 4–6 weeks depending on the specific SSRI and the duration of use. Fluoxetine (Prozac), with its very long half-life, may require 6–8 weeks. Discuss timing with a psychedelic-informed prescriber.
Is 5-HTP safe to take alongside microdosing?
Not on dose days. 5-HTP is a direct serotonin precursor that increases serotonin synthesis. Combined with psilocybin's receptor activation on the same day, there is a meaningful theoretical serotonin syndrome risk, particularly at higher 5-HTP doses (above 100mg). Some microdosers take 5-HTP on off days — particularly the day after a dose day — as a purported serotonin replenishment strategy. Whether this is pharmacologically beneficial is not established, but taking it on off days rather than dose days significantly reduces the interaction risk.
Continue reading
Explore the other cluster pages in this guide series.
How to start microdosing safely — complete guide →
Microdosing for depression — evidence and cautions→
Microdosing and ADHD — medication cautions→
Who should avoid microdosing — contraindications→
Risks and side effects — full guide→
Finding psychedelic-informed healthcare providers→
Medical & legal disclaimer: This page is for educational and harm reduction purposes only. It does not constitute medical advice. Interaction information is drawn from pharmacological inference, case reports, and clinical trial data — not from controlled human interaction studies in most cases. Do not stop or adjust any prescription medication without medical supervision. Psilocybin is a controlled substance in most jurisdictions. If you experience a medical emergency, call your local emergency services immediately.